newsfilter
← Latest News
GlobeNewswire·

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Announced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial; clinical proof-of-platform established with potential applicability across a broad range of diseasesAdvanced OMEGA